Matching articles for "mFLUSIVA"
Seasonal Influenza Vaccination: 2026-2027
The Medical Letter on Drugs and Therapeutics • October 12, 2026; (Issue 1765)
Annual influenza vaccination is recommended for all persons
≥6 months old without a contraindication. Influenza
vaccines available this season in the US are listed in Table...
Annual influenza vaccination is recommended for all persons
≥6 months old without a contraindication. Influenza
vaccines available this season in the US are listed in Table 3.
mFLUSIVA — An mRNA-Based Influenza Vaccine
The Medical Letter on Drugs and Therapeutics • September 14, 2026; (Issue 1763)
The FDA has licensed mFLUSIVA (Moderna), the first
mRNA-based influenza vaccine in the US, for prevention of
influenza in adults ≥50 years old. mFLUSIVA will be available
for the 2026-2027 influenza...
The FDA has licensed mFLUSIVA (Moderna), the first
mRNA-based influenza vaccine in the US, for prevention of
influenza in adults ≥50 years old. mFLUSIVA will be available
for the 2026-2027 influenza season. Three mRNA COVID-19
vaccines (Comirnaty, Spikevax, and mNEXSPIKE) and one
mRNA RSV vaccine (mRESVIA) are also licensed in the US.